Fig. 2From: Outcomes in patients with lacrimal gland carcinoma treated with definitive radiotherapy or eye-sparing surgery followed by adjuvant radiotherapyThe overall survival (OS), local progression-free survival (LPFS), and distant metastasis-free survival (DMFS) graphs of the whole cohort. For the entire cohort, 2-year OS, LPFS, and DMFS rates were 69.0, 76.7, and 71.4%, respectivelyBack to article page